What is the increased risk of NAION in patients using Ozempic for type 2 diabetes and obesity?
But some social media influencers say that taking a smaller-than-approved dose a trend called micro-dosing can lead to weight loss with fewer side effects
McGraw-Hill / Lange Rivera FB et al (2024): Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Cyrus Sedaghat before starting, plus ongoing monitoring after each dose adjustment
Their smaller molecular structure also facilitates better tissue penetration and lower production costs, which could enhance accessibility to these novel medications
Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days
